William Warnica1, Daniele Merico2, Gregory Costain1, Simon E Alfred1, John Wei3, Christian R Marshall3, Stephen W Scherer3, Anne S Bassett4. 1. Clinical Genetics Research Program, Centre for Addiction and Mental Health, Ontario, Canada. 2. The Centre for Applied Genomics and Program in Genetics and Genome Biology, The Hospital for Sick Children, Ontario, Canada. 3. The Centre for Applied Genomics and Program in Genetics and Genome Biology, The Hospital for Sick Children, Ontario, Canada; Department of Molecular Genetics and McLaughlin Centre, Ontario, Canada. 4. Clinical Genetics Research Program, Centre for Addiction and Mental Health, Ontario, Canada; Department of Psychiatry, University of Toronto, Ontario, Canada; Department of Psychiatry, University Health Network, Toronto, Ontario, Canada; Division of Cardiology, Department of Medicine, University Health Network, Toronto, Ontario, Canada. Electronic address: anne.bassett@utoronto.ca.
Abstract
BACKGROUND: MicroRNAs (miRNAs) are key regulators of gene expression in the human genome and may contribute to risk for neuropsychiatric disorders. miRNAs play an acknowledged role in the strongest of genetic risk factors for schizophrenia, 22q11.2 deletions. We hypothesized that in schizophrenia there would be an enrichment of other rare copy number variants (CNVs) that overlap miRNAs. METHODS: Using high-resolution genome-wide microarrays and rigorous methods, we compared the miRNA content of rare CNVs in well-characterized cohorts of schizophrenia cases (n = 420) and comparison subjects, excluding 22q11.2 CNVs. We also performed a gene-set enrichment analysis of the predicted miRNA target genes. RESULTS: The schizophrenia group was enriched for the proportion of individuals with a rare CNV overlapping a miRNA (3.29-fold increase over comparison subjects, p < .0001). The presence of a rare CNV overlapping a miRNA remained a significant predictor of schizophrenia case status (p = .0072) in a multivariate logistic regression model correcting for total CNV size. In contrast, comparable analyses correcting for CNV size showed no enrichment of rare CNVs overlapping protein-coding genes. A gene-set enrichment analysis indicated that predicted target genes of recurrent CNV-overlapped miRNAs in schizophrenia may be functionally enriched for neurodevelopmental processes, including axonogenesis and neuron projection development. Predicted gene targets driving these results included CAPRIN1, NEDD4, NTRK2, PAK2, RHOA, and SYNGAP1. CONCLUSIONS: These data are the first to demonstrate a genome-wide role for CNVs overlapping miRNAs in the genetic risk for schizophrenia. The results provide support for an expanded multihit model of causation, with potential implications for miRNA-based therapeutics.
BACKGROUND: MicroRNAs (miRNAs) are key regulators of gene expression in the human genome and may contribute to risk for neuropsychiatric disorders. miRNAs play an acknowledged role in the strongest of genetic risk factors for schizophrenia, 22q11.2 deletions. We hypothesized that in schizophrenia there would be an enrichment of other rare copy number variants (CNVs) that overlap miRNAs. METHODS: Using high-resolution genome-wide microarrays and rigorous methods, we compared the miRNA content of rare CNVs in well-characterized cohorts of schizophrenia cases (n = 420) and comparison subjects, excluding 22q11.2 CNVs. We also performed a gene-set enrichment analysis of the predicted miRNA target genes. RESULTS: The schizophrenia group was enriched for the proportion of individuals with a rare CNV overlapping a miRNA (3.29-fold increase over comparison subjects, p < .0001). The presence of a rare CNV overlapping a miRNA remained a significant predictor of schizophrenia case status (p = .0072) in a multivariate logistic regression model correcting for total CNV size. In contrast, comparable analyses correcting for CNV size showed no enrichment of rare CNVs overlapping protein-coding genes. A gene-set enrichment analysis indicated that predicted target genes of recurrent CNV-overlapped miRNAs in schizophrenia may be functionally enriched for neurodevelopmental processes, including axonogenesis and neuron projection development. Predicted gene targets driving these results included CAPRIN1, NEDD4, NTRK2, PAK2, RHOA, and SYNGAP1. CONCLUSIONS: These data are the first to demonstrate a genome-wide role for CNVs overlapping miRNAs in the genetic risk for schizophrenia. The results provide support for an expanded multihit model of causation, with potential implications for miRNA-based therapeutics.
Authors: Anne S Bassett; Gregory Costain; Wai Lun Alan Fung; Kathryn J Russell; Laura Pierce; Ronak Kapadia; Ronald F Carter; Eva W C Chow; Pamela J Forsythe Journal: J Psychiatr Res Date: 2010-11 Impact factor: 4.791
Authors: Kawther Abu-Elneel; Tsunglin Liu; Francesca S Gazzaniga; Yuhei Nishimura; Dennis P Wall; Daniel H Geschwind; Kaiqin Lao; Kenneth S Kosik Journal: Neurogenetics Date: 2008-06-19 Impact factor: 2.660
Authors: Farid Radmanesh; Ahmet Okay Caglayan; Jennifer L Silhavy; Cahide Yilmaz; Vincent Cantagrel; Tarek Omar; Başak Rosti; Hande Kaymakcalan; Stacey Gabriel; Mingfeng Li; Nenad Sestan; Kaya Bilguvar; William B Dobyns; Maha S Zaki; Murat Gunel; Joseph G Gleeson Journal: Am J Hum Genet Date: 2013-03-07 Impact factor: 11.025
Authors: G Kirov; A J Pocklington; P Holmans; D Ivanov; M Ikeda; D Ruderfer; J Moran; K Chambert; D Toncheva; L Georgieva; D Grozeva; M Fjodorova; R Wollerton; E Rees; I Nikolov; L N van de Lagemaat; A Bayés; E Fernandez; P I Olason; Y Böttcher; N H Komiyama; M O Collins; J Choudhary; K Stefansson; H Stefansson; S G N Grant; S Purcell; P Sklar; M C O'Donovan; M J Owen Journal: Mol Psychiatry Date: 2011-11-15 Impact factor: 15.992
Authors: Giorgos L Papadopoulos; Martin Reczko; Victor A Simossis; Praveen Sethupathy; Artemis G Hatzigeorgiou Journal: Nucleic Acids Res Date: 2008-10-27 Impact factor: 16.971
Authors: Carl F Schaefer; Kira Anthony; Shiva Krupa; Jeffrey Buchoff; Matthew Day; Timo Hannay; Kenneth H Buetow Journal: Nucleic Acids Res Date: 2008-10-02 Impact factor: 16.971
Authors: Amanda B Zheutlin; Clark D Jeffries; Diana O Perkins; Yoonho Chung; Adam M Chekroud; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Barbara A Cornblatt; Daniel H Mathalon; Thomas H McGlashan; Larry J Seidman; Elaine F Walker; Scott W Woods; Ming Tsuang; Tyrone D Cannon Journal: Neuropsychopharmacology Date: 2017-02-10 Impact factor: 7.853
Authors: Ece D Gamsiz; Laura N Sciarra; Abbie M Maguire; Matthew F Pescosolido; Laura I van Dyck; Eric M Morrow Journal: Neurotherapeutics Date: 2015-07 Impact factor: 7.620